Completed Study EXPLORE44-OLE Treatment Period (through W102)
No significant tolerability issues with AOC 1044
New (Non-Rollover) Participants
Permanently residing in the US and have a US primary health care provider
Documented dystrophin gene mutation that is amenable to exon 44 skipping
Age 2 or older at the time of consent
If previously treated with gene therapy for DMD, treatment and associated immunosuppressive regimen was more than 12 months before consent and in the opinion of the prescriber, participant has had an unsatisfactory treatment response
You may not be if
Rollover Participants
Prescence of any new condition or worsening of existing condition that could affect participant's safety or ability to comply with the program requirements
New (Non-Rollover) Participants
Recently treated with or on a clinical study for another investigation drug
Serious respiratory or cardiac dysfunction, or nearing end of life
Screening laboratory parameters do not meet protocol requirements
History of multiple drug allergies or to any component of AOC 1044
Participants who discontinued early from the treatment period of EXPLORE44 or EXPLORE44-OLE
